Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare Limited (SML) Receives Noc From RCGM, Dept. Of Biotechnology For Its Biosimilar Aflibercept - Intimation U/R 30 Of The SEBI (Listing Obligation And Disclosure Requirements) Regulations 2015

 This is to inform you that the Company, via its wholly owned subsidiary, Shilpa Biologicals Private Limited (SBPL), has received a NoC from RCGM, Dept of Biotechnology to approach the DCGI to conduct Clinical studies for its Biosimilar Aflibercept - a first from an Indian company. The product is a biosimilar version of EYLEA(r) of Regeneron for which currently there is no other biosimilar version on the Indian market.
25-04-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Submission In Compliance With Regulation 76 Of The Securities And Exchange Board Of India (Depositories And Participants) Regulations, 2018 For Quarter And Financial Year Ended 31 March, 2022.

 Pursuant to Regulation 76 of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, please find herewith enclosed certificate dated 22 April 2022 for the Quarter and Financial Year ended 31 March 2022 issued by M/s. VCAN & Associates, Practicing Company Secretaries, Hyderabad. Kindly take the same on record.
23-04-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Disclosure For Non Applicability As Large Entity: SEBI Circular No SEBI/HO/DDHS/CIR/P/2018/144, Dated November 26, 2018

 This is with regard to the SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018 144, dated, November 26, 2018 [''''SEBI Circular''''] w.r.t fund raising by issuance of Debt Securities by Large Entities, and Disclosures and compliances thereof by such Large Corporates. We hereby confirm that 'SHILPA MEDICARE LIMITED' [''''the Company''''] does not fall in the in the category of Large Corporates as per the applicability criteria given under Para 2.2 of the aforesaid SEBI Circular as on March 31, 2022. Kindly take the same on record and acknowledge the receipt.
23-04-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

 Pursuant to Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, Please find enclosed a Certificate dated April 05, 2022 for the quarter ended March 31, 2022, certifying that the details of securities dematerialized/rematerialized during the aforesaid period were maintained by 'M/s. Kfin Technologies Limited' (SEBI Registration No. INR000000221), the Registrar and Share Transfer Agent of Shilpa Medicare Limited.
23-04-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Sub: Submission In Compliance With Regulation 40(9) Of Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Financial Year Ended 31 March, 2022.

 Pursuant to Regulation 40(9) of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, Please find enclosed a Certificate dated 22 April 2022 for the financial year ended 31 March 2022 issued by VCAN Associates.
23-04-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Shareholding for the Period Ended March 31, 2022

 Shilpa Medicare Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2022. For more details, kindly Click here
09-04-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Submission In Compliance With Regulation 7(3) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Financial Year Ended 31 March, 2022.

 Submission in compliance with Regulation 7(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Financial Year ended 31 March, 2022.
08-04-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Statement Of Investor Complaints For The Quarter Ended March 2022

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Krishnappayya Desai Designation :- Any Other
07-04-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Update On Slump Sale Of Active Pharmaceutical Ingredient (API) Business Of The Company

 we hereby wish to inform you that, the Company with the approval of members through postal ballot has executed a Business Transfer Agreement, with Shilpa Pharma Lifesciences Limited (Formerly known as Shilpa Corporate Holdings Private Limited) a wholly owned subsidiary of the Company on 02 April 2022 and that the said transaction is expected to be completed within a period of 45 days or such other period as mutually agreed between the Parties.
02-04-2022
Bigul

SHILPA MEDICARE LTD. - 530549 - Closure of Trading Window

 In line with the provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 amended vide SEBI (Prohibition of Insider Trading) (Amendment) Regulations, 2018 read with Company's Code of Conduct for Regulating, Monitoring and Reporting of Trading by Insiders, it is hereby informed that the trading window of Shilpa Medicare Limited shall remain closed for dealing in securities of the Company for all Designated Employees/Persons and their immediate relatives with effect from 01 April 2022 till 48 hours after declaration of the financial results for the fourth quarter and financial year ending 31 March 2022. The date of board meeting for approving financial results for the quarter and financial year ending 31 March 2022 will be intimated in due course of time. The Exchange is requested to take the information on record.
31-03-2022
Next Page
Close

Let's Open Free Demat Account